Показано 0 из 0
Дата |
---|
17.05.2024 |
16.05.2024 |
15.05.2024 |
14.05.2024 |
13.05.2024 |
10.05.2024 |
09.05.2024 |
08.05.2024 |
07.05.2024 |
06.05.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.98
|
1.10
|
1.00
|
0.86
|
1.12
|
1.015
|
|
|
24 726.33
|
157.00
|
1.00
|
1.14
|
1.07
|
1.00
|
1.0788
|
1.05
|
|
|
18 380.61
|
131.00
|
1.01
|
1.19
|
1.1299
|
1.01
|
1.1299
|
1.08
|
|
|
8 835.35
|
55.00
|
1.00
|
1.20
|
1.12
|
1.01
|
1.13
|
1.045
|
|
|
6 372.70
|
55.00
|
1.01
|
1.15
|
1.12
|
1.01
|
1.12
|
1.07
|
|
|
13 078.72
|
87.00
|
1.06
|
1.18
|
1.0699
|
1.035
|
1.10
|
1.08
|
|
|
7 243.82
|
73.00
|
1.00
|
1.08
|
1.07
|
1.07
|
1.07
|
1.07
|
|
|
561.34
|
22.00
|
1.01
|
1.10
|
1.05
|
1.05
|
1.08
|
1.08
|
|
|
1 217.08
|
40.00
|
1.00
|
1.10
|
1.035
|
1.00
|
1.08
|
1.03
|
|
|
15 558.31
|
120.00
|
1.00
|
1.07
|
1.005
|
1.00
|
1.07
|
1.00
|
|
|
11 791.08
|
76.00
|
Estrella Immunopharma, Inc. operates as a preclinical-stage biopharmaceutical company. The Company focuses on developing CD19 and CD22-targeted T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella Immunopharma serves customers worldwide.